SQ Innovation

An Innovative, Market Ready Solution For A $1B+ Indication

About this Event

SQ Innovation is a privately-held Swiss biopharmaceutical company with U.S. offices in Burlington, MA. They have developed a novel drug-device combination for treating fluid overload in adult patients with chronic heart failure.

Heart failure is the second leading cause of inpatient treatment for Medicare recipients. Unfortunately those stays are often extended for several days by fluid overload which is treated with IV diuretics. SQ Innovation has developed Lasix® ONYU to provide patients with effective diuretic treatment without the need for hospital admission. It is a subcutaneous infuser that provides hospital IV-strength diuresis for at-home use, improving the process for patients, payors, and healthcare providers.

SQ Innovation has received tentative approval from the FDA and is finalizing their packaging and commercial infrastructure for launch which is scheduled for October 2025. They already have partnerships in place with several distributors, and 8 hospital systems have committed to the program upon launch.

Watch our webinar with Pieter Muntendam, MD, President and CEO of SQ Innovation, to hear how the company with a market potential of more than $1B, a launch that is just months away, and a plan to break even by the end of 2026, offers a unique opportunity for life sciences investors.

Video On Demand

– Recorded

May 22

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.